A subgroup analysis of the AZA-AML-001 study—which randomized patients >65 years of age with newly diagnosed AML to azacitidine versus conventional care regimens (CCR)—found no difference in outcomes of FLT3-mutated versus FLT3 wild type patients, although only 18 patients were included in this analysis, limiting its power [36]. Here, FLT3 is linked to acute myeloid leukemia.